Literature DB >> 29305737

Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation.

Gerard Quigley1, Mustafa Al Ani1, Abdul Nadir2.   

Abstract

Entities:  

Keywords:  Jaundice; Obeticholic acid; Primary biliary cholangitis; Ursodeoxycholic acid

Mesh：

Substances：

Year:  2018        PMID： 29305737     DOI： 10.1007/s10620-017-4900-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  9 in total

1.  Primary biliary cirrhosis.

Authors:  Keith D Lindor; M Eric Gershwin; Raoul Poupon; Marshall Kaplan; Nora V Bergasa; E Jenny Heathcote
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

2.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Authors:  Brent A Neuschwander-Tetri; Rohit Loomba; Arun J Sanyal; Joel E Lavine; Mark L Van Natta; Manal F Abdelmalek; Naga Chalasani; Srinivasan Dasarathy; Anna Mae Diehl; Bilal Hameed; Kris V Kowdley; Arthur McCullough; Norah Terrault; Jeanne M Clark; James Tonascia; Elizabeth M Brunt; David E Kleiner; Edward Doo
Journal:  Lancet       Date:  2014-11-07       Impact factor: 79.321

3.  Obeticholic Acid in Primary Biliary Cholangitis.

Authors:  Lisa A Spacek; Steven F Solga
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245

Review 4.  Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

5.  Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.

Authors:  Ewa Wunsch; Jocelyn Trottier; Malgorzata Milkiewicz; Joanna Raszeja-Wyszomirska; Gideon M Hirschfield; Olivier Barbier; Piotr Milkiewicz
Journal:  Hepatology       Date:  2014-07-30       Impact factor: 17.425

6.  When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?

Authors:  Claudia O Zein; Paul Angulo; Keith D Lindor
Journal:  Clin Gastroenterol Hepatol       Date:  2003-03       Impact factor: 11.382

7.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Authors:  Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

8.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

Authors:  Gideon M Hirschfield; Andrew Mason; Velimir Luketic; Keith Lindor; Stuart C Gordon; Marlyn Mayo; Kris V Kowdley; Catherine Vincent; Henry C Bodhenheimer; Albert Parés; Michael Trauner; Hanns-Ulrich Marschall; Luciano Adorini; Cathi Sciacca; Tessa Beecher-Jones; Erin Castelloe; Olaf Böhm; David Shapiro
Journal:  Gastroenterology       Date:  2014-12-11       Impact factor: 22.682

9.  Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona.

Authors:  Susanna Tan; Napatkamon Ayutyanont; Bikash Bhattarai; Zohreh Movahedi; Lakshmi Jayaram; Robert Gish; Abdul Nadir
Journal:  BMJ Open Gastroenterol       Date:  2017-09-25
  9 in total
  2 in total

Review 1.  Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.

Authors:  Melissa Palmer; Arie Regev; Keith Lindor; Mark I Avigan; Lara Dimick-Santos; William Treem; John F Marcinak; James H Lewis; Frank A Anania; Daniel Seekins; Benjamin L Shneider; Naga Chalasani
Journal:  Aliment Pharmacol Ther       Date:  2019-11-25       Impact factor: 8.171

2.  Clarification of Obeticholic Acid Dosing: Response to "Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation" by Quigley et al.

Authors:  Cynthia Feng
Journal:  Dig Dis Sci       Date:  2018-05-10       Impact factor: 3.199
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.